1. Home > Latest Topics >

Question 11: Effect of HAP/VAP on medical costs

20 June, 2018

question_11_5


LATEST TOPICS

Navigating antibiotic resistance in community-acquired pneumonia: Insights from Vietnam
29 October, 2024
Optimising antibiotic therapy: Insights on transitioning from intravenous to oral treatment for community-acquired pneumonia
27 September, 2024
Community-acquired pneumonia in Cambodia: Navigating the growing challenge of AMR
30 June, 2024
Managing Infectious Diseases in Emergency Medicine: A Specialist’s Approach
10 April, 2024
Advancing standardised diagnosis and treatment of acute infectious disease: Insights from an expert in theory–technique integration
08 April, 2024

RELATED ARTICLES

Gram-negative pneumonia: combination therapy and the role of quinolones
06 July, 2022
Fluoroquinolones in the management of hospital-acquired pneumonia
20 June, 2023
Levofloxacin in the Treatment of Hospital-Acquired Pneumonia: Insights into Antibiotic Resistance and Tolerance
18 October, 2023
Observing the Development of Quinolones from the Rational Application of Antibacterial Drugs During the COVID-19 Pandemic
21 March, 2023
Under the new medical reform, there are challenges for the rational use of antibiotics, making it necessary to adopt coping strategies
20 April, 2023